Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.2800
+0.0060 (2.19%)
At close: Oct 23, 2026, 4:00 PM EDT
0.2850
+0.0050 (1.79%)
After-hours: Oct 23, 2026, 7:48 PM EDT
Propanc Biopharma Employees
As of June 30, 2026, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Propanc Biopharma the 43,732nd largest employer in the world and 7,256th in the United States.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$9,897,478
Market Cap
1.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 2 | 0 | - | 2 | 0 |
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 24 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Kairos Pharma | 4 |
| XORTX Therapeutics | 3 |
| Oragenics | 3 |
PPCB News
- 1 day ago - Propanc Biopharma Inc trading halted, news pending - TheFly
- 2 days ago - CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - GlobeNewsWire
- 2 days ago - Propanc Biopharma announces 1-for-10 reverse stock split - TheFly
- 2 days ago - Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - GlobeNewsWire
- 8 days ago - Propanc Biopharma announces new preclinical research from PRP programs - TheFly
- 8 days ago - Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells - GlobeNewsWire
- 10 days ago - Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer - GlobeNewsWire
- 17 days ago - Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma - TheFly